At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
AMG 714 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
In Brief
A Phase 2 clinical trial evaluating AMG 714, Placebo, and 2 other interventions for Celiac Disease. Completed, enrolled 64 participants across 3 sites.
Detailed Summary
This study is designed to evaluate the efficacy and safety of AMG 714 for the attenuation of the effects of gluten exposure in adult patients with celiac disease during a gluten challenge.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCeliac Disease
CountriesFinland
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartApr 2016
Primary CompletionFeb 2017
Study CompletionMar 2017
TodayJul 2026
First PostedDec 22, 2015
Enrollment StartApr 13, 2016
Primary CompletionFeb 15, 2017
Study CompletionMar 14, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.5 years ago
Interventions
AMG 714biological
AMG 714 administered by subcutaneous injection
Placebobiological
Matching placebo to AMG 714 administered by subcutaneous injection
Placebo Gluten Challengeother
Gluten-free cookies (Finnish rusks)
Gluten Challengeother
Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving